The American Association of Clinical Endocrinologists/American College of Endocrinology consensus statement also recommends either a GLP-1RA or SGLT2i as a preferred treatment option (either as first-line or, more typically, second-line treatment after metformin) over alternative options such as a dipeptidyl peptidase-4 inhibitor, a thiazolidinedione (TZD), or a sulfonylurea (SU), for patients with T2D and ASCVD, stage 3 CKD, or heart failure with reduced ejection fraction [2]
Compounded semaglutide is not FDA-approved and is not established as equivalent to Ozempic or Wegovy
Panpetch, W., Hiengrach, P., Nilgate, S., Tumwasorn, S., Somboonna, N., Wilantho, A., Chatthanathon, P., Prueksapanich P., & Leelahavanichkul, A
While Noom Clinical includes some access to medical professionals, its core offering revolves around cognitive behavioral therapy (CBT) and goal tracking
The medication is administered as a once-weekly subcutaneous injection, with dosing typically initiated at 0.25 mg weekly and gradually escalated over 16 weeks (0.250.51.01.72.4 mg
Sipping water between meals rather than during them is a commonly recommended adjustment